Zobrazeno 1 - 10
of 413
pro vyhledávání: '"Mark V, Pauly"'
This book examines the behavior of individuals at risk and insurance industry decision makers involved in selling, buying and regulation. It compares their actions to those predicted by benchmark models of choice derived from classical economic theor
Autor:
Michael J. Pennock, Zhongyuan Yu, Karen B. Hirschman, Kara Pepe, Mark V. Pauly, Mary D. Naylor, William B. Rouse
Publikováno v:
IEEE Journal of Translational Engineering in Health and Medicine, Vol 6, Pp 1-12 (2018)
While the use of evidence-based interventions (EBIs) has been advocated by the medical research community for quite some time, uptake of these interventions by healthcare providers has been slow. One possible explanation is that it is challenging for
Externí odkaz:
https://doaj.org/article/816397e05c324b2f9cdcb55c5a85c53f
Autor:
Karen B, Hirschman, Eleanor, Rivera, Justine S, Sefcik, Kathleen, McCauley, Alexandra L, Hanlon, Mark V, Pauly, Matthew J, Press, Mary D, Naylor
Publikováno v:
Journal of Gerontological Nursing. 48:7-13
The purpose of the current in-depth qualitative study was to explore the experiences of older adults and family caregivers in primary care. Twenty patients and caregivers from six Comprehensive Primary Care Plus (CPC+) practices' Patient and Family A
Autor:
Molly Frean, Mark V. Pauly
Publikováno v:
International Journal of the Economics of Business. 30:31-49
Autor:
Alexandra L, Hanlon, Mark V, Pauly, Liming, Huang, Alicia J, Lozano, Karen B, Hirschman, Kathleen, McCauley, Matthew, Press, Mary D, Naylor
Publikováno v:
J Healthc Manag
GOAL: The objective of this retrospective, observational study is to assess the mediating effect of medical complexity on the relationship between social vulnerability and four acute care resource use outcomes, specifically numbers of hospitalization
Publikováno v:
Journal of Benefit-Cost Analysis. 13:166-181
The relationship between costs and health benefits of branded pharmaceuticals remains controversial. This paper examines the incremental costs incurred for incremental health benefits gained from the largest available sample of cost-effectiveness stu
Autor:
LAWTON ROBERT BURNS, MARK V. PAULY
Publikováno v:
The Milbank Quarterly.
Publikováno v:
SSRN Electronic Journal.
Autor:
Mark V. Pauly
Publikováno v:
Risk Analysis. 43:884-885
Publikováno v:
Value in Health. 24:1476-1483
Objectives Cost-effectiveness analysis of branded pharmaceuticals presumes that both cost (or price) and marginal effectiveness levels are exogenous. This assumption underlies most judgments of the cost-effectiveness of specific drugs. In this study,